Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer

Immune checkpoint inhibitors (ICI) for early-stage non-small cell lung cancer (NSCLC) have been approved to improve outcomes and reduce recurrence. Biomarkers for patient selection are needed. In this paper, we proposed an inflammasome-based risk score (IRS) system for prognosis and prediction of IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsao, Chih-Cheng, Wu, Hsin-Hung, Wang, Ying-Fu, Shen, Po-Chien, Wu, Wen-Ting, Chen, Huang-Yun, Dai, Yang-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313462/
https://www.ncbi.nlm.nih.gov/pubmed/35884843
http://dx.doi.org/10.3390/biomedicines10071539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313462/
https://www.ncbi.nlm.nih.gov/pubmed/35884843
http://dx.doi.org/10.3390/biomedicines10071539

Ejemplares similares